



Company Overview

Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development.

Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

Jun 3 2019, 6:55 AM EDT

Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

May 20 2019, 8:30 AM EDT

Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update

May 15 2019, 7:30 AM EDT

Stock Overview

Symbol	HTBX
Exchange	Nasdaq
Market Cap	25.68m
Last Price	\$0.7539
52-Week	\$0.6659 - \$2.53

06/17/2019 03:59 PM EDT

Investor Relations

investorrelations@heatbio.com

Management Team

Jeffrey Wolf

Founder, Chairman and CEO

Jeff Hutchins, Ph.D.

Chief Scientific and Operating Officer

George Peoples, M.D., FACS

Chief Medical Advisor

Lori McDermott, RN, BSN, MS, PMP

Vice President, Clinical Development

Janice Marie McCourt, R.P.h, M.B.A.

Vice President, Business Development

Gary Vinson

Vice President, Chemistry and Manufacturing Controls (CMC)

Robert J. Jakobs

Vice President of Finance and Secretary

Matthew M. Seavey, Ph.D.

Senior Director of Research

Heat Biologics, Inc.

801 Capitola Drive
Suite 12
Durham, NC 27713

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.